- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04828655
Analysis of Bioparametric Measures for Correlating Daily Habits and Reducing Blood Pressure
Análisis de Medidas bioparamétricas Para Correlacionar Los hábitos Diarios y Reducir la tensión Arterial
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
In the Valencian Community, 93% of deaths appear to be related to (non-communicable) diseases such as: obesity, hypertension and diabetes. In 2013, cardiovascular diseases were the leading cause of death in women (34.4%) and the second in men (28.0%). There is a forecast that overweight and obesity will reach levels of 89% and 85% in men and women, respectively, by 2030. This will result in an increase in the obesity-related prevalence of coronary heart disease by 97%. The promotion of research on arterial hypertension and how it could be reduced is one of the basic pillars in decreasing the prevalence and incidence in the Spanish population. Research should anticipate and develop treatments and vaccines that prevent new scenarios of widespread infection.
Therefore, the main objective is to study the effects of the use of a mobile application plus recommendations based on a Mediterranean diet on the intake of micronutrients from natural sources (not drugs) on health indicators, cardiovascular parameters (blood pressure...), physical condition and body composition in the adult Spanish population.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Alicante, Spanien, 03690
- Alejandro Martínez Rodríguez
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Over 40 years old
- Healthy.
- Blood pressure levels slightly elevated but less than 140 mm Hg and/or diastolic pressure less than 90 mm Hg.
- Smartphone access
Exclusion Criteria:
- Subjects with diseases.
- Consumption of drugs and/or supplements.
- Subjects with food intolerances/allergies.
- Subjects with muscle or joint injury.
- Subjects with impossibility to follow up the intervention.
- Refusal of informed consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: CONTROL GROUP
Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity.
Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
|
|
|
Experimental: EXPERIMENTAL GROUP
Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning.
Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
|
Specific diet program and moderate physical activity, all guided and mediated by a mobile application.
As well as the recording and monitoring of periodic evaluations of health indicators.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cardiovascular variables; heart rate.
Zeitfenster: 9 months
|
Heart rate measurement done with an activity wristband.
|
9 months
|
|
Cardiovascular variables; blood pressure.
Zeitfenster: 9 months
|
Measurement of blood pressure (systolic and diastolic) with a digital tensiometer.
|
9 months
|
|
Physical condition; time.
Zeitfenster: 9 months
|
The evaluation of the physical condition will be carried out by means of the mile test, in which the subjects have to cover this distance walking, and in the shortest possible time.
|
9 months
|
|
Body Composition - Bioimpedance
Zeitfenster: 9 months
|
Assessment of body composition using the TANITA (Tokyo, Japan) validated bioimpedance scale to obtain the results of fat mass, fat-free mass and visceral mass.
|
9 months
|
|
Weight
Zeitfenster: 9 months
|
The weight of the subjects will be obtained using the TANITA (Tokyo, Japan).
From the body mass and height data, the BMI (kg/m2) will be obtained.
|
9 months
|
|
Height
Zeitfenster: 9 months
|
The height of the subjects will be measured with the SECA 123 stadiometer (Hamburg, Germany).
From the body mass and height data, the BMI (kg/m2) will be obtained.
|
9 months
|
|
Body Composition - Skinfolds
Zeitfenster: 9 months
|
The kinanthropometric assessment will be carried out using the methodology proposed for the restricted profile by the International Society for the Development of Kineanthropometry (ISAK).
The material used to measure skinfolds will be a plicometer.
|
9 months
|
|
Body Composition - Perimeters
Zeitfenster: 9 months
|
The kinanthropometric assessment will be carried out using the methodology proposed for the restricted profile by the International Society for the Development of Kineanthropometry (ISAK).
The material used to measure perimeters will be a tape.
|
9 months
|
|
Body Composition - Diameters
Zeitfenster: 9 months
|
The kinanthropometric assessment will be carried out using the methodology proposed for the restricted profile by the International Society for the Development of Kineanthropometry (ISAK).
The material used to measure diameters will be a pachymeter.
|
9 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Alejandro Martínez Rodríguez, Alicante University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- UA-2020-04-16
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .